Abstract Details
|
Amit Verma, MD, MBBS, FAAN
(The Methodist Neurological Institute)
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| Cormac A. O'Donovan, MD (Wake Forest University) | Dr. O'Donovan has nothing to disclose. |
| Philippe Ryvlin, MD, PhD (Unit 301) | Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle/Angelini. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB pharma. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini pharma. The institution of Dr. Ryvlin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB pharma. The institution of Dr. Ryvlin has received research support from Swiss National Fund. The institution of Dr. Ryvlin has received research support from European Commission (Horizon Europe). |
| No disclosure on file | |
| Joana Moreira | Joana Moreira has received personal compensation for serving as an employee of BIAL. |
| Francisco Rocha | Francisco Rocha has received personal compensation for serving as an employee of BIAL - Portela. |
| Todd Grinnell, PhD | Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc.. |
| David E. Blum, MD | Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics. |
| Hailong Cheng | No disclosure on file |